Method of treatment of tp53 wild-type tumors with 2',2'-difluoro-5-aza-2'-deoxycytidine or prodrugs thereof
AssigneeEpigenetics Pharma LLC
InventorRichard DAIFUKU
Life of this patent
Estimating the term…
Abstract
This disclosure provides methods and strategies for inhibiting the growth of TP53 wild-type cancer cells, comprising contacting the cell with 2′,2′-difluoro-5-aza-2′-deoxycytidine or a 2′,2′-difluoro-5-aza-2′-deoxycytidine prodrug. Also provided are related methods for treating a cancer characterized by having wild-type TP53 in a subject in need thereof.
Claims20
A method for inhibiting the growth of a TP53 wild-type cancer cell, comprising contacting the TP53 wild-type cancer cell with 2′,2′-difluoro-5-aza-2′-deoxycytidine or a 2′,2′-difluoro-5-aza-2′-deoxycytidine prodrug or a composition comprising 2′,2′-difluoro-5-aza-2′-deoxycytidine or a 2′,2′-difluoro-5-aza-2′-deoxycytidine prodrug and a pharmaceutically acceptable carrier, diluent or excipient.
(canceled)
A method of treating a cancer characterized by having wild-type TP53, comprising administering to a subject in need thereof a therapeutically effective amount of 2′,2′-difluoro-5-aza-2′-deoxycytidine or a 2′,2′-difluoro-5-aza-2′-deoxycytidine prodrug or a composition comprising 2′,2′-difluoro-5-aza-2′-deoxycytidine or a 2′,2′-difluoro-5-aza-2′-deoxycytidine prodrug and a pharmaceutically acceptable carrier, diluent or excipient.
(canceled)
-38. (canceled)
Dependencies are inferred from the claim text.